Auto-Injector Course

Auto-Injector course banner

The Epinephrine Auto-Injector E-Learning Course is an interactive tool developed to educate, assist, and support our local school boards, schools, and staff who have direct contact with students at risk for anaphylaxis. The course assists schools with the implementation of Sabrina’s Law (Sabrina’s Law– An Act to Protect Anaphylactic Pupils, 2006).

The course content increases knowledge of the issues surrounding anaphylaxis and prepares staff to respond appropriately in the event of an emergency.

Course chapters include:

  • Understanding Anaphylaxis
  • Signs and Symptoms of Anaphylaxis
  • Prevention and Emergency Protocol
  • Administering an Auto-Injector

How do I get my certificate? 

When the e-learning course is complete, a certificate will be generated and displayed (PDF format).  You may then print and/or save your certificate.  Your certificate is accessible by logging in to your e-learning account, and selecting 'Get my auto-injector certificate' atop the course page.

(This course was developed based on the Ministry of Education, Anaphylaxis Resource Kit which includes Anaphylaxis in Schools & Other Settings 3rd Edition: Copyright © 2005-2014 Canadian Society of Allergy and Clinical Immunology)

Recall Notice to Public: Allerject

Alert Date: 

Thursday, October 29, 2015 - 3:30pm

Location: 

Canada

Sanofi recalls all lots of Allerject (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths)
 

What you need to know:

Sanofi-aventis Canada Inc., in consultation with Health Canada, is recalling all lots of Allerject (0.15 mg/0.15mL and 0.3 mg/0.3 mL strength epinephrine auto-injectors) from the Canadian market.

Allerject is a medication delivery device that prescribed to adults and children diagnosed with severe allergic reactions, and is used as an emergency treatment.

This recall is due to issues that may potentially affect the delivery of the required amount of the drug, epinephrine.

This means that individuals may not receive a full dose of the medication from the recalled Allerject devices.

The affected lot numbers are as follows:

  • Allerject Pre-filled Autoinjector (DIN02382059 – 0.15mg/0.15mL epinephrine)
  • Allerject Pre-filled Autoinjector (DIN02382067 – 0.3mg/0.3mL epinephrine)

 

What should you do?

Health Canada is advising anyone with an Allerject device (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths) to return the device to the pharmacy where they initially got it to receive a replacement epinephrine auto-injector with the same dose.

For those affected by this recall, Health Canada is also advising that in the event that a life-threatening allergic reaction (anaphylaxis) occurs before you can obtain a replacement auto injector, use your Allerject device as directed by your healthcare provider, and then seek emergency medical attention.

Speak with your healthcare professional if you are concerned about your health or your child’s health.

Report any adverse events to Health Canada.

For more information, or to report an adverse event, please visit the Health Canada website.